TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02882321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxidative Phosphorylation Inhibitor IACS-010759
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxidative Phosphorylation Inhibitor IACS-010759
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxidative Phosphorylation Inhibitor IACS-010759
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxidative Phosphorylation Inhibitor IACS-010759
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT00313105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation counseling
Description: individual visits
Study: NCT01454986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALXN1007
Description: Single dose, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALXN1007
Description: Single dose, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALXN1007
Description: Single dose, IV
Study: NCT02454933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Once daily tablet 80 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Once daily tablet 80 mg
Study: NCT02454933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: 10mg/kg q2w (IV) infusion
Study: NCT00725491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganirelix
Description: On day 6 of recFSH treatment, Org 37462 treatment will start by daily SC administration (0.25 mg) up to and including the day of hCG administration.
Study: NCT01454986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALXN1007
Description: Single dose, IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single dose, IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single dose, IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single dose, IV
Study: NCT00725491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triptorelin
Description: a daily dose of 0.05 mg SC is to be injected. Triptorelin treatment will start in the luteal phase at day 21-24 of the menstrual cycle. Treatment with recFSH will start 14 days later if treatment with triptorelin has resulted in downregulation, i.e. serum E2 \<= 50 pg/ml (\<= 200pmol/l). In case the hypogonadotropic state is not reached after 14 days of pretreatment, the dose of triptorelin will be increased to 0.1 mg. If downregulation is not reached within 28 days of pre-treatment with triptorelin, the subject will be discontinued from further hormonal treatment. The daily dose of triptorelin is sustained up to and including the day of hCG.
Study: NCT00133965

Intervention type: BEHAVIORAL
Intervention: Dignity Psychotherapy
Description: At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires.will also receive three visits by a mental health professional over a period of five to seven days. You will be asked to fill out some brief questionnaires during this session which ask about feelings about your illness, symptoms, emotional reactions, and support you have available. The second meeting will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the Research Staff.The third meeting you will also be asked to fill out several questionnaires,including a specific questionnaire regarding your thoughts about the Dignity Psychotherapy Intervention. Total time commitment for this study should be approximately 120-150 minutes.

Intervention type: BEHAVIORAL
Intervention: Supportive Psychotherapy
Description: you will receive the standard care you normally would receive, but will also receive three visits by a mental health professional over a period of five to seven days. The initial visit will take approximately 45 minutes. You will be asked to fill out brief questionnaires (described above) during this session.A second contact will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the research staff. During this second session, you will have the opportunity to discuss with a supportive research therapist issues or topics relevant to your experience of coping with cancer.The third and final contact,you will be asked you to fill out questionnaires similar to those you filled out at the beginning of the study. Total time commitment for this study should be approximately 120-150 minutes.
Study: NCT01454986

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single dose, IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single dose, IV
Study: NCT01090739

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOPAS Treatment for Fecal Incontinence
Description: The TOPAS Treatment for Fecal Incontinence is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.
Study: NCT02964234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment
Description: Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Three group sessions (breast cancer education; diet; physical activity) 1.5 hours 3 times across 3 weeks
Study: NCT02511106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 80 mg/40 mg
Description: The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
Study: NCT02882321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02511106

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo AZD9291 80 mg/40 mg
Description: The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
Study: NCT03574636

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT guidance
Description: OCT guide stent implantation
Study: NCT02511106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label AZD9291 80 mg/40 mg
Description: Eligible patients will be offered open-label osimertinib upon recurrence and in the absence of intervening systemic anti-cancer therapy.
Study: NCT03574636

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS guidance
Description: IVUS guide stent implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: QCA
Description: QCA guide stent implantation
Study: NCT03445624

Intervention type: DRUG
Intervention: Infliximab
Description: follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy

Intervention type: DRUG
Intervention: Infliximab
Description: follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy
Study: NCT02886052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist guided Internet-CBT for insomnia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Study: NCT02049242

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: triple tourniquet
Description: Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single tourniquet
Description: Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
Study: NCT00297323

Intervention type: DRUG
Intervention: Topiramate
Description: 75 patients over the age of 2 years old with epilepsy.
Study: NCT01565330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: single dose IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: single dose IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: single dose IV injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: single dose IV injection
Study: NCT03844126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transition classes
Description: 90 minutes spent with patients and their families (separately) to review the changes and challenges associated with healthcare transition and help alleviate some of the barriers traditionally associated with this process.
Study: NCT02393963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride (placebo group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
Study: NCT01968018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCI/acetaminophen
Description: Participants will receive tablet of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication is 1 to 2 tablets every 4 to 6 hours as needed for pain relief up to maximum of 8 tablets per day.
Study: NCT04729166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured education and follow-up
Description: This structured educational material was developed by the authors on the basis of the literature. Interventions of the study were carried out in the 32nd-42nd week of pregnancy, 3rd-7th day postpartum, and at the 1st month. At first stage, a 15-20-minute education was given to the pregnant women in the study group in the breastfeeding room of the facility, educational booklets were distributed. The main emphasis parts of the education were repeated with a standard summary information form at each follow-up.
Study: NCT00091299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Study: NCT04495114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40g carbohydrate load (Apple juice)
Description: A 40g carbohydrate drink will be administered to subjects with non-insulin dependent type 2 diabetes 3 hours prior to their operation. This is standard practice in subjects without diabetes.
Study: NCT04103333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Administered as specified in the treatment arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Administered as specified in the treatment arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Administered as specified in the treatment arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Administered as specified in the treatment arm.
Study: NCT04700696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Recovery Support
Description: Weekly visits with peer who has lived experience related to child welfare and addiction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Recovery Support
Description: Weekly visits with peer who has lived experience related to child welfare and addiction
Study: NCT04103333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Administered as specified in the treatment arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Administered as specified in the treatment arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Administered as specified in the treatment arm.
Study: NCT04700696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Treatment Drug Court with Medications for Opioid Use Disorders (MOUD)
Description: Incentivized to participate in Family Treatment Drug Court with option for Medications for Opioid Use Disorders (MOUD)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relational Skill Building based on the Nurturing Parenting Program (NPP)
Description: Home-based parenting support
Study: NCT01446965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearable defibrillator
Description: LifeVest wearable defibrillator
Study: NCT04103333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Administered as specified in the treatment arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Administered as specified in the treatment arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Administered as specified in the treatment arm.
Study: NCT03160131

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuro Vision Technology
Description: Training using Neuro Vision Technology
Study: NCT03957629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Oral medication of Tenofovir Disoproxil Fumarate 300mg once per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Oral medication of Tenofovir Disoproxil Fumarate 300mg once per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Interferon alfa 2a
Description: Subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
Study: NCT00403429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study: NCT04515979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib 300 mg BID and pembrolizumab 200 mg IV
Description: Vactosertib 300 mg orally (PO) BID(5 days on/2days off) and pembrolizumab 200 mg IV (Q3W).
Study: NCT03732274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEW-7197
Description: TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart. Durvalumab will be administered as a dose of 1500 mg every 4weeks.
Study: NCT03131531

Intervention type: OTHER
Intervention: Patient registry
Description: Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures

Intervention type: OTHER
Intervention: Patient registry
Description: Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures

Intervention type: OTHER
Intervention: Patient registry
Description: Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
Study: NCT03650218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THIODERM STRONG
Description: Soft tissue filler containing crosslinked hyaluronic acid and Na-hyaluronate, supplemented with lidocaine hydrochloride as ancillary substance.
Study: NCT04319939

Intervention type: OTHER
Intervention: Assist Control Mode and Pressure Support Mode Mechanical Ventilation
Description: Diaphragm ultrasound measurements (end expiration and peak inspiration thickness) will be performed in assist control mode and pressure support mode mechanical ventilation in each participant. The participant will thus serve as his/her own control for these interventions.
Study: NCT01224288

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion CT scan
Description: DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
Study: NCT03978689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUE-101
Description: CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A\&B and in combination in Parts C\&D according to the schedule described in the protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: CUE-101
Description: CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A\&B and in combination in Parts C\&D according to the schedule described in the protocol.

Intervention type: DRUG
Group type: OTHER
Intervention: KEYTRUDA®, Pembrolizumab
Description: KEYTRUDA® is first-line therapy in HPV16 and HLA A\*0201-positive recurrent and/or metastatic HNSCC patients given in combination with CUE-101 in Parts C\&D according to the schedule described in the protocol.
Study: NCT02528643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study: NCT00345865

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and with or without rituximab. Leukapheresis is to begin on Day 5.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and with or without rituximab. Leukapheresis is to begin on Day 5.
Study: NCT04103333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Administered as specified in the treatment arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Administered as specified in the treatment arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Administered as specified in the treatment arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Administered as specified in the treatment arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Administered as specified in the treatment arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Collection
Description: Administered as specified in the treatment arm.
Study: NCT02607176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heweizhixie capsule
Description: 3 #, Tid, Oral for 3 days
Study: NCT01709071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Sabin-IPV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose adjuvanted Sabin-IPV
Study: NCT00345865

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and with or without rituximab. Leukapheresis is to begin on Day 5.
Study: NCT04136769

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Visceral Debranching
Description: Visceral debranching is defined as a vascular reconstruction with the aim of ensuring a sufficient arterial blood flow to the mesentery and liver after the subsequently planned tumor resection, which usually comprises ligation of the gastroduodenal artery or other relevant collateral vessels. All open vascular procedures can be employed for visceral debranching. Examples are aorto-visceral or iliaco-visceral bypasses using autologous vein or an allogeneic graft, or re-insertion of the superior mesenteric artery or celiac trunk into the aorta.
Study: NCT01194076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-day intensive treatment
Description: Exposure Based Cognitive Behavioral Therapy administered in 10 appointments over 5 days with an added focus on training parents to be exposure coaches
Study: NCT00345865

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: irradiation therapy
Description: Patients undergo total body irradiation (TBI) twice daily on days -4 to -1.~* \> 1000 cGy to whole lung, kidney, or abdominal bath.~* \> 3000 cGy to spinal cord, myocardium, mediastinum, lumbar periaortic lymph nodes.~* \> 3600 cGy to whole brain.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: irradiation therapy
Description: Patients undergo total body irradiation (TBI) twice daily on days -4 to -1.~* \> 1000 cGy to whole lung, kidney, or abdominal bath.~* \> 3000 cGy to spinal cord, myocardium, mediastinum, lumbar periaortic lymph nodes.~* \> 3600 cGy to whole brain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.~Continue G-CSF until absolute neutrophil count (ANC) \> 1500/μl x 3 consecutive days.~If ANC falls \<1000/μL, restart G-CSF.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.~Continue G-CSF until absolute neutrophil count (ANC) \> 1500/μl x 3 consecutive days.~If ANC falls \<1000/μL, restart G-CSF.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.~Continue G-CSF until absolute neutrophil count (ANC) \> 1500/μl x 3 consecutive days.~If ANC falls \<1000/μL, restart G-CSF.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.~Continue G-CSF until absolute neutrophil count (ANC) \> 1500/μl x 3 consecutive days.~If ANC falls \<1000/μL, restart G-CSF.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.~Continue G-CSF until absolute neutrophil count (ANC) \> 1500/μl x 3 consecutive days.~If ANC falls \<1000/μL, restart G-CSF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m\^2 over one hour BID on days -6 through -2 of BEAM conditioning regimen.
Study: NCT01709071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Middle dose Sabin-IPV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Middle dose adjuvanted Sabin-IPV